Ewing’s Sarcoma: Standard and Experimental Treatment Options

被引:0
|
作者
Vivek Subbiah
Pete Anderson
Alexander J. Lazar
Emily Burdett
Kevin Raymond
Joseph A. Ludwig
机构
[1] University of Texas M.D. Anderson Cancer Center,Department of Pediatrics
[2] University of Texas M.D. Anderson Cancer Center,Department of Pathology
[3] Rice University,Division of Bio
[4] M.D. Anderson Cancer Center,Medical Engineering
来源
Current Treatment Options in Oncology | 2009年 / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ewing sarcoma family tumors (EWS), which include classic Ewing’s sarcoma in addition to primitive neuroectodermal tumor and Askin tumor, are the second most common variety of primary bone cancer to afflict adolescents and young adults. Multi-disciplinary care incorporating advances in diagnosis, surgery, chemotherapy, and radiation has substantially improved the survival rate of patients with localized Ewing sarcoma to nearly 70%. Unfortunately, those advances have not significantly changed the long-term outcome for those with metastatic or recurrent disease; 5-year survival remains less than 25%. This apparent therapeutic plateau exists despite extensive effort during the last four decades to optimize the efficacy of cytotoxic chemotherapy through combination of chemotherapies of mechanistically diverse action, dose-dense scheduling (provided as frequently as every 2 weeks), increased adjuvant treatment duration, and higher dosage per cycle (facilitated with parallel strides in supportive care incorporating growth factors). As has already occurred for malignancies such as breast or colon cancer, the “-omics-based” revolution has enhanced our understanding of the molecular changes responsible for Ewing’s tumor formation and identified a number of potential targets (such as IGF-1R or mTOR) amenable to biological therapy. It has also created both a challenge and an opportunity to develop predictive biomarkers capable of selecting patients most likely to benefit from targeted therapy. In this review, we discuss current standard-of-care for patients with Ewing’s sarcoma and highlight the most promising experimental therapies in early-phase clinical trials.
引用
收藏
页码:126 / 140
页数:14
相关论文
共 50 条
  • [1] Ewing's Sarcoma: Standard and Experimental Treatment Options
    Subbiah, Vivek
    Anderson, Pete
    Lazar, Alexander J.
    Burdett, Emily
    Raymond, Kevin
    Ludwig, Joseph A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2009, 10 (1-2) : 126 - 140
  • [2] Experimental therapies in Ewing's sarcoma
    Windsor, Rachael
    Strauss, Sandra
    Seddon, Beatrice
    Whelan, Jeremy
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (02) : 143 - 159
  • [3] Current treatment for Ewing's sarcoma
    Thacker, MM
    Temple, HT
    Scully, SP
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (02) : 319 - 331
  • [4] Treatment of femoral Ewing's sarcoma
    Terek, RM
    Brien, EW
    Marcove, RC
    MEyers, PA
    Lane, JM
    Healey, JH
    CANCER, 1996, 78 (01) : 70 - 78
  • [5] Diagnosis and treatment of Ewing's sarcoma
    Iwamoto, Yukihide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (02) : 79 - 89
  • [6] Ewing's Sarcoma of the Stomach; Rare Case of Ewing's Sarcoma and Suggestion of New Treatment Strategy
    Kim, Hyo-Sin
    Kim, Sungsoo
    Min, Young-Don
    Kee, Keun-Hong
    Hong, Ran
    JOURNAL OF GASTRIC CANCER, 2012, 12 (04) : 258 - 261
  • [7] Treatment of pelvic Ewing's sarcoma with multidisciplinary treatment
    Delepine, N
    Alkallaf, S
    Sokolov, T
    Cornille, H
    Delepine, G
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 279 - 279
  • [8] Potential approaches to the treatment of Ewing's sarcoma
    Yu, Hongjiu
    Ge, Yonggui
    Guo, Lianying
    Huang, Lin
    ONCOTARGET, 2017, 8 (03) : 5523 - 5539
  • [9] Treatment strategies for metastatic Ewing's sarcoma
    Pinkerton, CR
    Bataillard, A
    Guillo, S
    Oberlin, O
    Fervers, B
    Philip, T
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (11) : 1338 - 1344
  • [10] Preoperative radiochemotherapy in the treatment of Ewing's sarcoma
    Rube, C
    Schuck, A
    Hillmann, A
    Dunst, J
    Jurgens, H
    Willich, N
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 493 - 493